glp-1 agonist for prediabetes Medications: Everything You Need to Know New GLP-1 Guidelines for Type

[DOI] [PubMed] [Google Scholar] 2.Ong K.L., Stafford L.K., McLaughlin S.A., Boyko E.J., Vollset S.E., Smith A.E., Dalton B.E., Duprey J., Cruz J.A., Hagins H., et al

Results of cardiovascular safety studies have not shown any indication of cardiovascular harm, with possible suggestion of cardiovascular benefit

Such molecules could have therapeutic potential for T2D, obesity, cardiovascular disease and even neurodegeneration

The diabetes indication segment accounted for the largest share of the market

Some plans may require documentation of previous weight loss attempts or evidence of obesity-related health concerns